Coherus, In Ring As A Biosimilar Contender, Hopes To Smack Down Humira
Executive Summary
Six-year-old biosimilar specialist could be first company to launch a biosimilar version of Neulasta, but the possibility of a biosimilar version of Humira has investors ogling.
You may also be interested in...
Amgen's Amjevita Approved As First Biosimilar To AbbVie's Humira
Adalimumab-atto is approved for seven indications on the reference product label but lacks four others that are protected by orphan product exclusivity; launch timing is unclear due 'patent dance' litigation.
FDA Biosimilar Policy Continues To Evolve With Approval Of Sandoz Erelzi
Third biosimilar approved in US brings another iteration of FDA thinking on labeling and naming; etanercept-szzs, which references Amgen's Enbrel, suggests agency might be backtracking on its suffix policy.
AbbVie v. Amgen Round One: Humira Biosimilar Infringes 10 Patents, Suit Claims
'Amgen is speaking out of both sides of its mouth', AbbVie contends, promising suit on dozens more patents.